FLT3

Mark Levis | ASCO 2018 | Maintenance therapy with gilteritinib in FLT3-ITD+ AML

L:

Mark Levis, John Hopkins University, Baltimore, US, discusses at the 2018 American Society of Oncology Annual Meeting, the design of the ongoing phase III trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF